← Back to list
08.02.44, Revakinagene taroretcel-lwey (Encelto®)
Act
by Dec 29, 2025
Effective date
Dec 29, 2025
Identified
Oct 2, 2026
Summary
Independence Blue Cross has reissued Policy 08.02.44 establishing coverage criteria for revakinagene taroretcel-lwey (Encelto®), a newly FDA-approved gene therapy for adults with idiopathic macular telangiectasia type 2 (MacTel). The policy defines strict medical necessity requirements including documented diagnosis via imaging, visual acuity thresholds, exclusionary conditions, and prior surgical history limitations. All other uses remain experimental/investigational and not covered.
Get alerts when payers change rules like this one
We check Independence Blue Cross and other payers every day and email you when a change matches your specialty and state.
Get Independence Blue Cross alertsPolicy Monitoring is free. No card required.
What to do
by Dec 29, 2025 · 6 steps
01Billing team must implement coverage criteria for HCPCS code J3403 (Revakinagene taroretcel-lwey, per implant) in the billing system and prior authorization workflow.
02Ophthalmology providers must document all required medical necessity elements before claim submission: (1) confirmed MacTel type 2 diagnosis with fluorescein angiography/OCT/OCT angiography showing fluorescein leakage plus at least one additional feature (hyperpigmentation >500 microns from fovea, retinal opacification, crystalline deposits, right-angle vessels, or lamellar cavities); (2) BCVA of 54-letter ETDRS or 20/80 Snellen or better; (3) absence of ocular/periocular infections, Endo-SFM hypersensitivity, glaucoma, severe diabetic retinopathy, uveitis, or confounding ocular disease; (4) no intraretinal hyperreflectivity or neovascularization with associated hemorrhage, hard exudate, or fluid; (5) no prior vitrectomy, penetrating keratoplasty, trabeculectomy, trabeculoplasty, lens removal in prior 3 months, or YAG laser within 4 weeks; and (6) no prior Encelto implantation in the affected eye.
03Add documentation checklist to ophthalmology templates.
04Update prior authorization forms to require all criteria documentation.
05Claims submitted without complete medical necessity documentation or that do not meet all criteria will be denied.
06Flag any claims for off-label uses as experimental/investigational and deny unless approved under off-label coverage policy.
Codes mentioned
J3403H35.071H35.072H35.073
Original notice
08.02.44, Revakinagene taroretcel-lwey (Encelto®)
medpolicy.ibx.com · Always check the source before changing claims.
Related changes
See all Independence Blue Cross changes →MA08.013, Revakinagene taroretcel-lwey (Encelto®)LowEffective Dec 29, 2025 · Pharmacy08.02.44, Revakinagene taroretcel-lwey (Encelto®)MediumEffective Dec 29, 2025 · PharmacyMA08.013, Revakinagene taroretcel-lwey (Encelto®)MediumEffective Dec 29, 2025 · PharmacyBrowse every Independence Blue Cross change in the policy list